Neurofit Obtains Singapore Certification for 'Neurofit Aqua'... Expands Product Line to Target Southeast Asian Market

Neurofit, a specialized company in AI solutions for brain disease imaging, announced on the 11th that it has obtained medical device certification from the Singapore Health Sciences Authority (HSA) for its neurodegenerative brain imaging analysis software, ‘Neurophet AQUA’.

Last December, Neurofit received medical device certification from the HSA for its PET imaging automatic analysis software, ‘Neurophet SCALE PET.’ With the certification of its flagship product Neurophet AQUA alongside Neurophet SCALE PET, Neurofit is smoothly progressing its preparations to target the Southeast Asian medical market.

Neurophet AQUA is a brain imaging analysis medical device software that analyzes brain MRI (magnetic resonance imaging) using AI technology to assess brain atrophy and white matter degeneration observed in neurodegenerative diseases such as Alzheimer’s disease and vascular dementia.

Traditional brain imaging analysis products based on atlas software require about 8 to 24 hours for brain image segmentation and have a high failure rate in analysis, causing practical difficulties for medical professionals. Moreover, these products can only analyze brains based on Western standards, limiting their applicability to Asian brains.

Neurophet AQUA, based on an AI engine, can perform brain image segmentation and analysis within 5 minutes and boasts a 0% analysis failure rate, achieving a high success rate. It can analyze brain images regardless of race, age, or gender, and produces consistent analysis results from images obtained by various global MRI device manufacturers such as GE, Philips, and Canon.

Previously certified by the HSA, Neurophet SCALE PET is an AI-based imaging diagnostic software that quantitatively analyzes Alzheimer’s disease biomarkers by automatically analyzing brain images combining PET (positron emission tomography) and MRI scans. Neurofit plans to further enhance Neurophet AQUA and Neurophet SCALE PET to establish a global standard for Alzheimer’s disease diagnosis in the future.

Neurofit is accelerating its entry into the Southeast Asian market by collaborating with universities conducting diverse brain disease research in Singapore. In November last year, Neurofit signed a joint research agreement on brain imaging analysis with the Dementia Research Centre under the Lee Kong Chian School of Medicine at Nanyang Technological University, utilizing Neurophet AQUA to analyze local data held by the Dementia Research Centre.

Bin Jungil, CEO of Neurofit, said, “Following the certification of Neurophet SCALE PET, the certification of Neurophet AQUA expands the range of products that can enter Singapore, the medical industry hub of Southeast Asia. With active joint research ongoing with the Nanyang Technological University Dementia Research Centre, we will do our best in sales and marketing activities to ensure that Neurofit products are actively used in the Southeast Asian medical market.”

Meanwhile, according to data from the Korea Trade-Investment Promotion Agency (KOTRA), Singapore ranked high in the global medical innovation index in 2021 and is recognized as having an advanced medical system in the ASEAN region. The Singapore medical industry is expected to grow to $49 billion USD (approximately 65 trillion KRW) by 2029.